Current Report Filing (8-k)
March 30 2015 - 4:11PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): March 27, 2015
Commission File Number: 000-50768
ACADIA
Pharmaceuticals Inc.
(Exact name of Registrant as specified in its charter)
|
|
|
Delaware |
|
061376651 |
(State or other jurisdiction of
incorporation or organization) |
|
(IRS Employer
Identification No.) |
3611 Valley Centre Drive, Suite 300, San Diego, California 92130
(Address of principal executive offices)
858-558-2871
(Registrants Telephone number)
Not Applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 4.01 |
Changes in Registrants Certifying Accountant. |
(a)
The Audit Committee (the Committee) of the Board of Directors of ACADIA Pharmaceuticals Inc. (the Company) initiated a selection
process in the first half of March to determine the Companys independent registered public accounting firm for the fiscal year ending December 31, 2015, including the fiscal quarter ending March 31, 2015. As a result of this process,
on March 27, 2015, the Committee approved the appointment of Ernst & Young LLP (Ernst & Young) as the Companys independent registered public accounting firm for the fiscal year ending December 31, 2015.
(b)
During the two most recent fiscal years and in the
subsequent interim period through March 27, 2015, the Company has not consulted with Ernst & Young with respect to the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit
opinion that would have been rendered on the Companys consolidated financial statements, or any other matters set forth in Item 304(a)(2)(i) or (ii) of Regulation S-K.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
Date: March 30, 2015 |
|
|
|
ACADIA Pharmaceuticals Inc. |
|
|
|
|
|
|
|
|
By: |
|
/s/ Glenn F. Baity |
|
|
|
|
Name: |
|
Glenn F. Baity |
|
|
|
|
Title: |
|
EVP, General Counsel & Secretary |
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Sep 2023 to Sep 2024